Oncología Traslacional
ONCTRAS
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (22)
2024
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
2023
-
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
2021
-
Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78
-
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
ESMO open, Vol. 6, Núm. 4, pp. 100212
-
SEOM clinical guideline in ovarian cancer (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 961-968
2019
-
GEICO1601-ROLANDO: A multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
Future Science OA, Vol. 5, Núm. 2
-
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789
2018
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
-
SEOM Clinical Guideline in ovarian cancer (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1206-1212
-
Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy
Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593
2013
-
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525
2012
-
Progress against solid tumors in danger: The metastatic breast cancer example
Journal of Clinical Oncology
-
Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631
2009
-
Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375